A year af­ter FTC nixed Il­lu­mi­na buy­out, Soft­Bank bets $900M on PacBio's new vi­sion

A year af­ter the FTC killed Pa­cif­ic Bio­sciences’ $1.2 bil­lion buy­out by Il­lu­mi­na, Cal­i­for­nia’s small­er ge­nom­ic se­quenc­ing com­pa­ny has found a far dif­fer­ent group to fork over a for­tune.

The Wall Street Jour­nal re­port­ed Wednes­day that Soft­Bank, Japan­ese bil­lion­aire Masayoshi Son’s once-again prof­itable tech con­glom­er­ate, will in­vest $900 mil­lion in­to PacBio as they look to scale up pub­lic eq­ui­ty in­vest­ing and wade deep­er in­to biotech. Soft­Bank has in­vest­ed in six re­cent life sci­ences IPOs, the Jour­nal re­port­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER